Survival predictors of (177)Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)

PURPOSE: (177)Lu-Dotatate is an emerging treatment modality for patients with unresectable or metastatic well-differentiated NETs. This study examines survival predictors in patients who received (177)Lu-Dotatate. METHODS: A retrospective single-center review was conducted, examining 47 individuals...

Descripción completa

Detalles Bibliográficos
Autores principales: Swiha, Mina M., Sutherland, Duncan E. K., Sistani, Golmehr, Khatami, Alireza, Abazid, Rami M., Mujoomdar, Amol, Wiseman, Daniele P., Romsa, Jonathan G., Reid, Robert H., Laidley, David T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article – Clinical Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752529/
https://www.ncbi.nlm.nih.gov/pubmed/34110489
http://dx.doi.org/10.1007/s00432-021-03672-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752529/
https://www.ncbi.nlm.nih.gov/pubmed/34110489
http://dx.doi.org/10.1007/s00432-021-03672-w

Ejemplares similares